Who's Using GLP-1s Now? The 2026 Numbers, Explained
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
GLP-1 use has hit a new high. About 11% of U.S. adults now take a GLP-1 medication for weight loss, and 15% say they have tried one at some point, according to a July 2026 Gallup survey (Gallup). The latest numbers show who is using these drugs, what they are taking, and what is changing.
Who This Helps
This is for anyone curious about how common GLP-1 medications have become, whether you are considering one, already taking one, or just trying to understand a trend that keeps making headlines. It is also for family members who want the real numbers instead of the hype.
How Many People Use GLP-1s Now?
GLP-1 use for weight loss has climbed fast. The share of U.S. adults currently taking one rose to 11% in 2026, up from just 3% in 2024, and 15% now say they have used one at some point (Gallup). Awareness is nearly universal, with 91% of adults saying they know about these drugs.
A separate national poll that counts all reasons for use, not just weight loss, found about 1 in 8 adults currently taking a GLP-1 and roughly 1 in 5 having tried one (KFF). The two surveys measure slightly different things, but both point the same way: use is high and still rising.
Independent analyses have reached similar conclusions about how widespread these medicines have become in the United States (RAND).
Who Is Most Likely to Use One?
Use is not spread evenly. Adults ages 50 to 64 report the highest use at about 22%, while those 65 and older use them far less, at around 9% (KFF).
Women are more likely than men to take a GLP-1 or to have tried one, and use is especially high among people managing other conditions, with about 57% of adults with diabetes and 40% of those with heart disease saying they have used one (KFF).
Obesity Is Ticking Down as Use Rises
As GLP-1 use has grown, the national obesity rate has eased from a peak of 39.9% in 2022 to 36.4% in 2026, while the diabetes rate has leveled off after years of climbing (Gallup).
What this means for you: these trends move together, but that does not prove one caused the other. The weight figures also come from what people report about themselves, so treat the direction of the trend as more reliable than any single number.
Brand Name vs Compounded: What People Are Taking
Most users are on brand-name medicines like Ozempic, Wegovy, Mounjaro, and Zepbound, which make up about 68% of current use, compared with 19% using a compounded GLP-1 product and 12% who are unsure (Gallup).
There is real movement toward compounded products, though. About 35% of people using a compounded GLP-1 had switched from a brand-name drug, while only 10% moved the other way, and the top reason for switching was cost or insurance.
Do People Think They Work?
In the poll, most users called their medicine effective, and the numbers were similar for brand-name and compounded products, with roughly three-quarters of each group rating them effective or extremely effective (Gallup). That reflects how users feel, not a head-to-head clinical trial, and adults 65 and older reported lower effectiveness than younger users.
The Number Behind the Numbers: Cost
Cost is the thread running through all of this. About half of adults who have taken a GLP-1 say the drugs are difficult to afford, which helps explain why so many people shop around or switch products (KFF).
If price or provider questions are your sticking point, you can compare telehealth providers and transparent pricing, including HSA and FSA options, with the GLP Winner provider survey.
Final Takeaway
GLP-1 medications have moved from novelty to normal in a few short years. More than one in ten adults now use one for weight loss, and awareness is nearly everywhere.
The bigger story is that obesity is edging down while use climbs, even if the data cannot prove the link. That is a hopeful direction worth watching.
Brand-name drugs still lead, but cost is pushing more people toward compounded options. Where you land is a decision for you and your prescriber, with your budget in the room.
Numbers like these are a snapshot, not a verdict on any one person. Use them as context, then focus on what fits your health and your life.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
How many Americans take GLP-1 medications?
About 11% of U.S. adults currently take a GLP-1 for weight loss and 15% have tried one, according to a 2026 Gallup survey. A separate poll that counts all uses found roughly 1 in 8 adults currently taking one.
Who is most likely to use a GLP-1?
Adults ages 50 to 64 report the highest use, and women use them more than men. Use is also common among people with diabetes or heart disease, while adults 65 and older use them less.
Are more people using brand-name or compounded GLP-1s?
Brand-name medicines make up about two-thirds of current use, and compounded products about one in five. Many compounded users switched from a brand-name drug, most often because of cost or insurance.
Is obesity going down as GLP-1 use rises?
National surveys show obesity easing from its 2022 peak while GLP-1 use climbs. The trends move together, but that does not prove the drugs alone are the cause.
Why do people switch GLP-1 medications?
Cost and insurance are the leading reasons people switch, often from a brand-name drug to a compounded product. About half of users say GLP-1s are hard to afford.
Sources
Keep Reading
The Wegovy Pill passed 3 million prescriptions. What $149 self-pay covers, what the 25 mg dose costs, and how the pill compares to the shot.
CagriSema is under FDA review with a decision expected in 2026. See what the trials showed and how it compares to Wegovy and Zepbound.
The Medicare GLP-1 Bridge starts July 1, 2026. See who qualifies, which drugs cost $50, and how the prior authorization works step by step.
Categories
Curated by
